Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier

Mona Boules, Beth McMahon, Rui Wang, Lewis Warrington, Jennifer Stewart, Sally Yerbury, Abdul Fauq, Daniel J Mc Cormick, Elliott Richelson

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

NT69L, a neurotensin analog that crosses the blood-brain barrier, reduces body temperature, reverses apomorphine-induced climbing, haloperidol-induced catalepsy, and D-amphetamine- and cocaine-induced locomotor activity in rats. In this study we tested the development of tolerance to these effects of NT69L in rats. The blockade of apomorphine-induced climbing behavior and D-amphetamine- and cocaine-induced hyperactivity seen after a single acute injection did not show significant change with repeated daily injections of NT69L. Thus, for example, NT69L after five daily injections at a fixed dosage was as effective at reversing cocaine-induced hyperactivity as after the first injection. On the other hand, repeated daily injections of NT69L resulted in a diminished hypothermic response and a diminished anticataleptic effect against haloperidol. The effect of NT69L on blood glucose, cortisol, and thyroxine (T4) were all back to control levels after five daily injections. Thus, tolerance developed to NT69L after the first injection, when it was tested for causing hypothermia, blockade of haloperidol-induced catalepsy, and change in blood glucose, cortisol and T4 levels. Since tolerance did not develop to the effects of drugs acting as direct (apomorphine) or indirect (D-amphetamine and cocaine) agonists at dopamine receptors over the course of 5 days, these findings suggest a selective role of neurotensin in the modulation of dopamine neurotransmission. Furthermore, due to the lack of development of tolerance, NT69L or similar analogs might be useful in modulating certain behavioral effects of psychostimulants or have potential use as an antipsychotic drug in humans.

Original languageEnglish (US)
Pages (from-to)39-48
Number of pages10
JournalBrain Research
Volume987
Issue number1
DOIs
StatePublished - Oct 10 2003

Fingerprint

Neurotensin
Blood-Brain Barrier
Injections
Cocaine
Apomorphine
Haloperidol
Amphetamine
Catalepsy
Hydrocortisone
Blood Glucose
neurotensin 69L
Dopamine Agonists
Locomotion
Hypothermia
Body Temperature
Thyroxine
Synaptic Transmission
Antipsychotic Agents
Dopamine

Keywords

  • Apomorphine
  • Cocaine
  • D-Amphetamine
  • Haloperidol
  • NT69L

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier. / Boules, Mona; McMahon, Beth; Wang, Rui; Warrington, Lewis; Stewart, Jennifer; Yerbury, Sally; Fauq, Abdul; Mc Cormick, Daniel J; Richelson, Elliott.

In: Brain Research, Vol. 987, No. 1, 10.10.2003, p. 39-48.

Research output: Contribution to journalArticle

Boules, M, McMahon, B, Wang, R, Warrington, L, Stewart, J, Yerbury, S, Fauq, A, Mc Cormick, DJ & Richelson, E 2003, 'Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier', Brain Research, vol. 987, no. 1, pp. 39-48. https://doi.org/10.1016/S0006-8993(03)03227-X
Boules, Mona ; McMahon, Beth ; Wang, Rui ; Warrington, Lewis ; Stewart, Jennifer ; Yerbury, Sally ; Fauq, Abdul ; Mc Cormick, Daniel J ; Richelson, Elliott. / Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier. In: Brain Research. 2003 ; Vol. 987, No. 1. pp. 39-48.
@article{2b0015944ec446c3a40f3d066bd30713,
title = "Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier",
abstract = "NT69L, a neurotensin analog that crosses the blood-brain barrier, reduces body temperature, reverses apomorphine-induced climbing, haloperidol-induced catalepsy, and D-amphetamine- and cocaine-induced locomotor activity in rats. In this study we tested the development of tolerance to these effects of NT69L in rats. The blockade of apomorphine-induced climbing behavior and D-amphetamine- and cocaine-induced hyperactivity seen after a single acute injection did not show significant change with repeated daily injections of NT69L. Thus, for example, NT69L after five daily injections at a fixed dosage was as effective at reversing cocaine-induced hyperactivity as after the first injection. On the other hand, repeated daily injections of NT69L resulted in a diminished hypothermic response and a diminished anticataleptic effect against haloperidol. The effect of NT69L on blood glucose, cortisol, and thyroxine (T4) were all back to control levels after five daily injections. Thus, tolerance developed to NT69L after the first injection, when it was tested for causing hypothermia, blockade of haloperidol-induced catalepsy, and change in blood glucose, cortisol and T4 levels. Since tolerance did not develop to the effects of drugs acting as direct (apomorphine) or indirect (D-amphetamine and cocaine) agonists at dopamine receptors over the course of 5 days, these findings suggest a selective role of neurotensin in the modulation of dopamine neurotransmission. Furthermore, due to the lack of development of tolerance, NT69L or similar analogs might be useful in modulating certain behavioral effects of psychostimulants or have potential use as an antipsychotic drug in humans.",
keywords = "Apomorphine, Cocaine, D-Amphetamine, Haloperidol, NT69L",
author = "Mona Boules and Beth McMahon and Rui Wang and Lewis Warrington and Jennifer Stewart and Sally Yerbury and Abdul Fauq and {Mc Cormick}, {Daniel J} and Elliott Richelson",
year = "2003",
month = "10",
day = "10",
doi = "10.1016/S0006-8993(03)03227-X",
language = "English (US)",
volume = "987",
pages = "39--48",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier

AU - Boules, Mona

AU - McMahon, Beth

AU - Wang, Rui

AU - Warrington, Lewis

AU - Stewart, Jennifer

AU - Yerbury, Sally

AU - Fauq, Abdul

AU - Mc Cormick, Daniel J

AU - Richelson, Elliott

PY - 2003/10/10

Y1 - 2003/10/10

N2 - NT69L, a neurotensin analog that crosses the blood-brain barrier, reduces body temperature, reverses apomorphine-induced climbing, haloperidol-induced catalepsy, and D-amphetamine- and cocaine-induced locomotor activity in rats. In this study we tested the development of tolerance to these effects of NT69L in rats. The blockade of apomorphine-induced climbing behavior and D-amphetamine- and cocaine-induced hyperactivity seen after a single acute injection did not show significant change with repeated daily injections of NT69L. Thus, for example, NT69L after five daily injections at a fixed dosage was as effective at reversing cocaine-induced hyperactivity as after the first injection. On the other hand, repeated daily injections of NT69L resulted in a diminished hypothermic response and a diminished anticataleptic effect against haloperidol. The effect of NT69L on blood glucose, cortisol, and thyroxine (T4) were all back to control levels after five daily injections. Thus, tolerance developed to NT69L after the first injection, when it was tested for causing hypothermia, blockade of haloperidol-induced catalepsy, and change in blood glucose, cortisol and T4 levels. Since tolerance did not develop to the effects of drugs acting as direct (apomorphine) or indirect (D-amphetamine and cocaine) agonists at dopamine receptors over the course of 5 days, these findings suggest a selective role of neurotensin in the modulation of dopamine neurotransmission. Furthermore, due to the lack of development of tolerance, NT69L or similar analogs might be useful in modulating certain behavioral effects of psychostimulants or have potential use as an antipsychotic drug in humans.

AB - NT69L, a neurotensin analog that crosses the blood-brain barrier, reduces body temperature, reverses apomorphine-induced climbing, haloperidol-induced catalepsy, and D-amphetamine- and cocaine-induced locomotor activity in rats. In this study we tested the development of tolerance to these effects of NT69L in rats. The blockade of apomorphine-induced climbing behavior and D-amphetamine- and cocaine-induced hyperactivity seen after a single acute injection did not show significant change with repeated daily injections of NT69L. Thus, for example, NT69L after five daily injections at a fixed dosage was as effective at reversing cocaine-induced hyperactivity as after the first injection. On the other hand, repeated daily injections of NT69L resulted in a diminished hypothermic response and a diminished anticataleptic effect against haloperidol. The effect of NT69L on blood glucose, cortisol, and thyroxine (T4) were all back to control levels after five daily injections. Thus, tolerance developed to NT69L after the first injection, when it was tested for causing hypothermia, blockade of haloperidol-induced catalepsy, and change in blood glucose, cortisol and T4 levels. Since tolerance did not develop to the effects of drugs acting as direct (apomorphine) or indirect (D-amphetamine and cocaine) agonists at dopamine receptors over the course of 5 days, these findings suggest a selective role of neurotensin in the modulation of dopamine neurotransmission. Furthermore, due to the lack of development of tolerance, NT69L or similar analogs might be useful in modulating certain behavioral effects of psychostimulants or have potential use as an antipsychotic drug in humans.

KW - Apomorphine

KW - Cocaine

KW - D-Amphetamine

KW - Haloperidol

KW - NT69L

UR - http://www.scopus.com/inward/record.url?scp=0142106466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142106466&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(03)03227-X

DO - 10.1016/S0006-8993(03)03227-X

M3 - Article

C2 - 14499944

AN - SCOPUS:0142106466

VL - 987

SP - 39

EP - 48

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -